An Expanded Access Protocol of Oral Rociletinib (CO-1686) as Epidermal Growth Factor Receptor (EGFR)-Directed Therapy for Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation

Trial Profile

An Expanded Access Protocol of Oral Rociletinib (CO-1686) as Epidermal Growth Factor Receptor (EGFR)-Directed Therapy for Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Rociletinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 17 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top